Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Sep;65(9):3852–3856. doi: 10.1128/iai.65.9.3852-3856.1997

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

D N Taylor 1, C O Tacket 1, G Losonsky 1, O Castro 1, J Gutierrez 1, R Meza 1, J P Nataro 1, J B Kaper 1, S S Wasserman 1, R Edelman 1, M M Levine 1, S J Cryz 1
PMCID: PMC175550  PMID: 9284163

Abstract

To provide optimum protection against classical and El Tor biotypes of Vibrio cholerae O1, a single-dose, oral cholera vaccine was developed by combining two live, attenuated vaccine strains, CVD 103-HgR (classical, Inaba) and CVD 111 (El Tor, Ogawa). The vaccines were formulated in a double-chamber sachet; one chamber contained lyophilized bacteria, and the other contained buffer. In the first study, 23 U.S. adult volunteers received CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(8), 10(7), or 10(6) CFU, CVD 111 alone at 10(7) CFU, or placebo. In the second study, 275 Peruvian adults were randomized to receive CVD 103-HgR at 10(9) CFU plus CVD 111 at 10(9) or 10(8) CFU, CVD 111 alone at 10(9) CFU, CVD 103-HgR alone at 10(9) CFU, or placebo. Three of 15 U.S. volunteers who received CVD 111 at 10(7) or 10(8) CFU developed mild diarrhea, compared to none of 4 who received CVD 111 at 10(6) CFU and 1 of 4 who received placebo. Twelve (63%) of 19 vaccine recipients shed the El Tor vaccine strain. All but one volunteer developed significant Ogawa and Inaba vibriocidal antibody titers. Volunteers who received CVD 111 at 10(7) CFU had geometric mean Ogawa titers four to five times higher than those of volunteers who received the lower dose. In the second study, all dosage regimens were well tolerated in Peruvians. About 20% of volunteers who received CVD 111 at the high dose excreted the El Tor organism, compared to 7% in the low-dose group. CVD 111 was detected in the stools of two placebo recipients, neither of whom had symptoms or seroconverted. In all vaccine groups, 69 to 76% developed fourfold rises in Inaba vibriocidal antibodies. Among those who received the bivalent vaccine, 53 to 75% also developed significant rises in Ogawa vibriocidal antibodies. We conclude that it is feasible to produce a single-dose, oral bivalent vaccine that is safe and immunogenic against both biotypes (El Tor and classical) and both serotypes (Inaba and Ogawa) of cholera for populations in both developed and developing parts of the world.

Full Text

The Full Text of this article is available as a PDF (139.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Besser R. E., Feikin D. R., Eberhart-Phillips J. E., Mascola L., Griffin P. M. Diagnosis and treatment of cholera in the United States. Are we prepared? JAMA. 1994 Oct 19;272(15):1203–1205. [PubMed] [Google Scholar]
  2. Clemens J. D., van Loon F., Sack D. A., Rao M. R., Ahmed F., ChakrabortY J., Kay B. A., Khan M. R., Yunus M. D., Harris J. R. Biotype as determinant of natural immunising effect of cholera. Lancet. 1991 Apr 13;337(8746):883–884. doi: 10.1016/0140-6736(91)90207-6. [DOI] [PubMed] [Google Scholar]
  3. Clements M. L., Levine M. M., Young C. R., Black R. E., Lim Y. L., Robins-Browne R. M., Craig J. P. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145(4):465–473. doi: 10.1093/infdis/145.4.465. [DOI] [PubMed] [Google Scholar]
  4. Gicquelais K. G., Baldini M. M., Martinez J., Maggi L., Martin W. C., Prado V., Kaper J. B., Levine M. M. Practical and economical method for using biotinylated DNA probes with bacterial colony blots to identify diarrhea-causing Escherichia coli. J Clin Microbiol. 1990 Nov;28(11):2485–2490. doi: 10.1128/jcm.28.11.2485-2490.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Glass R. I., Libel M., Brandling-Bennett A. D. Epidemic cholera in the Americas. Science. 1992 Jun 12;256(5063):1524–1525. doi: 10.1126/science.1598586. [DOI] [PubMed] [Google Scholar]
  6. Gotuzzo E., Butron B., Seas C., Penny M., Ruiz R., Losonsky G., Lanata C. F., Wasserman S. S., Salazar E., Kaper J. B. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun. 1993 Sep;61(9):3994–3997. doi: 10.1128/iai.61.9.3994-3997.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kaper J. B., Michalski J., Ketley J. M., Levine M. M. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR. Infect Immun. 1994 Apr;62(4):1480–1483. doi: 10.1128/iai.62.4.1480-1483.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kenner J. R., Coster T. S., Taylor D. N., Trofa A. F., Barrera-Oro M., Hyman T., Adams J. M., Beattie D. T., Killeen K. P., Spriggs D. R. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis. 1995 Oct;172(4):1126–1129. doi: 10.1093/infdis/172.4.1126. [DOI] [PubMed] [Google Scholar]
  9. Lagos R., Avendaño A., Prado V., Horwitz I., Wasserman S., Losonsky G., Cryz S., Jr, Kaper J. B., Levine M. M. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun. 1995 Feb;63(2):707–709. doi: 10.1128/iai.63.2.707-709.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Levine M. M., Kaper J. B., Herrington D., Ketley J., Losonsky G., Tacket C. O., Tall B., Cryz S. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet. 1988 Aug 27;2(8609):467–470. doi: 10.1016/s0140-6736(88)90120-1. [DOI] [PubMed] [Google Scholar]
  11. Levine M. M., Young C. R., Black R. E., Takeda Y., Finkelstein R. A. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol. 1985 Feb;21(2):174–179. doi: 10.1128/jcm.21.2.174-179.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lockman H., Kaper J. B. Nucleotide sequence analysis of the A2 and B subunits of Vibrio cholerae enterotoxin. J Biol Chem. 1983 Nov 25;258(22):13722–13726. [PubMed] [Google Scholar]
  13. Simanjuntak C. H., O'Hanley P., Punjabi N. H., Noriega F., Pazzaglia G., Dykstra P., Kay B., Suharyono, Budiarso A., Rifai A. R. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis. 1993 Nov;168(5):1169–1176. doi: 10.1093/infdis/168.5.1169. [DOI] [PubMed] [Google Scholar]
  14. Su-Arehawaratana P., Singharaj P., Taylor D. N., Hoge C., Trofa A., Kuvanont K., Migasena S., Pitisuttitham P., Lim Y. L., Losonsky G. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis. 1992 Jun;165(6):1042–1048. doi: 10.1093/infdis/165.6.1042. [DOI] [PubMed] [Google Scholar]
  15. Suharyono, Simanjuntak C., Witham N., Punjabi N., Heppner D. G., Losonsky G., Totosudirjo H., Rifai A. R., Clemens J., Lim Y. L. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992 Sep 19;340(8821):689–694. doi: 10.1016/0140-6736(92)92231-4. [DOI] [PubMed] [Google Scholar]
  16. Tacket C. O., Losonsky G., Nataro J. P., Cryz S. J., Edelman R., Fasano A., Michalski J., Kaper J. B., Levine M. M. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis. 1993 Dec;168(6):1536–1540. doi: 10.1093/infdis/168.6.1536. [DOI] [PubMed] [Google Scholar]
  17. Tacket C. O., Losonsky G., Nataro J. P., Cryz S. J., Edelman R., Kaper J. B., Levine M. M. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1992 Oct;166(4):837–841. doi: 10.1093/infdis/166.4.837. [DOI] [PubMed] [Google Scholar]
  18. Taylor D. N., Killeen K. P., Hack D. C., Kenner J. R., Coster T. S., Beattie D. T., Ezzell J., Hyman T., Trofa A., Sjogren M. H. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis. 1994 Dec;170(6):1518–1523. doi: 10.1093/infdis/170.6.1518. [DOI] [PubMed] [Google Scholar]
  19. Waldor M. K., Mekalanos J. J. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science. 1996 Jun 28;272(5270):1910–1914. doi: 10.1126/science.272.5270.1910. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES